Abstract
The synthesis of new bisaryl thienocyclopentoxazolidine derivatives was achieved through a Suzuki cross-coupling procedure with the aim to enhance the previously reported cytotoxicity of the series. The biological activity, evaluated in the NCI's in vitro human disease-oriented tumor cell line screening panel, was however partially conserved by the pharmacomodulations.